References of "Expert Reviews of Pharmacoeconomics & Outcomes Research"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMicro Factors Bringing the Pharmaceutical Industry to a Seismic Shaking A Qualitative Research
Dierks, Raphaela Marie Louisa ULiege; Bruyère, Olivier ULiege; Reginster, Jean-Yves ULiege

in Expert Reviews of Pharmacoeconomics & Outcomes Research (2017), 17(3), 267-74

INTRODUCTION: Due to changing macro and micro factors, expiring patents and falling net income, pharmaceutical companies need to rethink their vertical business model. The trend shows cross-sectorial ... [more ▼]

INTRODUCTION: Due to changing macro and micro factors, expiring patents and falling net income, pharmaceutical companies need to rethink their vertical business model. The trend shows cross-sectorial partnerships and consolidation to remain and compete on the market. Areas covered: Quantitative research interviewing a target group of 25 key executives from small, mid and large global pharmaceutical companies rounded with qualitative literature research completing the analysis. Expert commentary: Uncertainty in the industry due to changing external factors i.e. pricing pressures, regulations or an economic slowdown, slowing down innovations and new drug outcomes. Pharmaceutical companies understand the existing hurdles, and are critically optimistic implementing new business models. Also, various stakeholders are included in the value chain due to their growing importance. CONCLUSION: During the next years, the industry will be restructured from volume towards value, and only pharmaceutical companies' clairaudient and reciprocate to the changes with an out-off the box thinking will be able to resist on the market. Small biotech companies should focus on research, and big pharmaceutical companies entering at development focusing on the process until the distribution. This execution business recommendation would enable the best know-how at the right point, mitigating the risk and enhancing the patient outcomes. [less ▲]

Detailed reference viewed: 22 (1 ULiège)
Full Text
Peer Reviewed
See detailCurrent review of the SarQoL®: a health-related quality of life questionnaire specific to sarcopenia
Beaudart, Charlotte ULiege; Reginster, Jean-Yves ULiege; Geerinck, Anton ULiege et al

in Expert Reviews of Pharmacoeconomics & Outcomes Research (2017), (On line),

INTRODUCTION: Sarcopenia, defined by a progressive and generalized loss of muscle mass and muscle function, is associated with many harmful clinical consequences. Several studies have reported the impact ... [more ▼]

INTRODUCTION: Sarcopenia, defined by a progressive and generalized loss of muscle mass and muscle function, is associated with many harmful clinical consequences. Several studies have reported the impact of sarcopenia on health-related quality of life (HRQoL) using generic quality of life (QoL) questionnaires. The results of these observational studies are quite heterogenous. Indeed, generic tools may not be able to detect subtle effects of sarcopenia on QoL. Recently, a sarcopenia-specific HRQoL questionnaire was developed and validated in a population of sarcopenic subjects to more accurately assess the impact of sarcopenia on QoL. Areas covered: The purpose of this review is to present evidence regarding the impact of sarcopenia on QoL and to introduce a new specific HRQoL questionnaire, the SarQoL®. Expert commentary: The self-administered SarQoL®, initially developed in French, comprises 55 items translated into 22 questions. The questionnaire has been shown to be understandable, valid, consistent, and reliable and can therefore be recommended for clinical and research purposes. The questionnaire is now available in 11 different languages with another 20 translations in progress. The instrument's sensitivity to change still needs to be assessed in future longitudinal studies. [less ▲]

Detailed reference viewed: 15 (3 ULiège)
Full Text
Peer Reviewed
See detailThe importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
Hiligsmann, Mickaël ULiege; Boonen, Annelies; Rabenda, Véronique ULiege et al

in Expert Reviews of Pharmacoeconomics & Outcomes Research (2012), 12(2), 159-66

Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the ... [more ▼]

Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost-effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost-effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges. [less ▲]

Detailed reference viewed: 73 (7 ULiège)